Iin Susanti, a representative from Bio Farma, expressed her commitment to contributing to global health advancement during the 26th Annual General Meeting of the DCVMN 2025 held in Denpasar, Bali on Friday.
"We want to contribute to advancing global health," said Susanti who was elected as Chair of the DCVMN Board for the 2026-2029 period.
With over 30 years of experience in the vaccine industry, Susanti brings a wealth of knowledge and expertise to her new role as Chair of the DCVMN Board.
Throughout her career, she has held numerous positions in vaccine R&D, manufacturing, quality control and assurance, business development and corporate transformation.
Formerly assigned as Operations Director, Susanti is currently the Director of Human Capital, for which talent development is one of her immediate undertakings and a personal interest.
Her background in pharmacy and Master's degree in Operations Management complement her expertise in the vaccine industry.
With a vast exposure to the vaccine ecosystem, Susanti has actively engaged with numerous international organizations, such as the World Health Organization (WHO), UNICEF, Gates Foundation.
Representing Indonesia at the DCVMN, Susanti is the third representative to be selected to occupy this strategic position, following Mahendra Suhardono and Adriansjah Azhari, who have also previously held several strategic positions in the network.
Established in 2000, DCVMN is a global network comprising 46 vaccine manufacturers from 17 developing countries across Asia, Africa, Europe, and Latin America, including Argentina, Bangladesh, Brazil, China, Ghana, India, Indonesia, Saudi Arabia, Senegal, Serbia, South Africa, South Korea, Thailand, and Vietnam.
This network aims to strengthen the capacity of vaccine manufacturers in developing countries through advocacy, fostering collaborations, increasing wallet share, and professional training on technology advancement, research and development, and knowledge transfer.
As Chair of the DCVMN Board, Susanti aims to promote equitable access to quality vaccines, strengthen collaboration among member countries and global institutions, and support investment in vaccine development capacity and innovation.
She also aims to promote equal access to quality vaccines that meet standards and are tested through the WHO PQ (WHO Prequalification) process, and to strengthen self-reliance among DCVMN members through closer cooperation.
However, she acknowledged that many challenges remain, including access to technology, the need for increased investment, the availability of raw materials to ensure a sustainable supply chain, human resources, and the implementation of digital automation.
Therefore, she also aims to encourage further collaboration with Bio Farma and other Indonesian manufacturers in developing vaccine innovations and ensuring their availability to the public.
Susanti stated that she will seek funding organizations and other relevant stakeholders to support the development of a resilient vaccine ecosystem in Indonesia and promote equal access to high-quality vaccines through harmonization with other relevant international organizations.
In an effort to address potential future pandemics, DCVMN will also continue to collaborate with various parties, especially the Coalition for Epidemic Preparedness Innovations (CEPI), which has a mission to ensure the availability of a vaccine for this pandemic within 100 days.
This collaboration will also continue to be strengthened to support the investment needed to expand vaccine development capacity.
The 26th Annual General Meeting of the Developing Countries Vaccine Manufacturers (DCVMN) 2025 took place in Sanur, Denpasar, Bali, from October 29 to 31, 2025.
Susanti expressed optimism that the meeting will further strengthen collaboration among DCVMN member countries, thereby advancing global health.
Related news: Bio Farma seeks public health protection, industrial sustainability
Related news: Bio Farma promotes collaboration to build resilient vaccine ecosystem
Reporter: Katriana
Editor: Yuni Arisandy Sinaga
Copyright © ANTARA 2025
